MODIFICATION
66 -- Methicillin-Resistant Staphylococcus Aureus (MRSA) PCRTesting
- Notice Date
- 1/28/2008
- Notice Type
- Modification
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Veterans Affairs;James J. Peters VA Medical Center;130 West Kingsbridge Road;Bronx NY 10468-3904
- ZIP Code
- 10468-3904
- Solicitation Number
- VA-243-08-RP-0094
- Archive Date
- 2/27/2008
- Point of Contact
- Anthony M Goldstone Special Projects Coordinator 718-741-4335
- E-Mail Address
-
Email your questions to Special Projects Coordinator
(Anthony.Goldstone@med.va.gov)
- Small Business Set-Aside
- N/A
- Description
- The Department of Veterans Affairs (VISN 3) Healthcare Network intends to negotiate a multi-award agreement with the following Food and Drug Administration (FDA) approved General Services Administration (GSA) companies to provide control and preventative measures for the active surveillance of Methicillin-Resistant Staphylococcus aureus (MRSA): Cepheid, 904 Caribbean Drive Sunnyvale, California 94089 for its GeneXpert System. The GeneXpert System combines sample preparation with real-time PCR amplification and detection for fully integrated and automated nucleic acid analysis. The system???s capability enables users to perform up to 16 different molecular tests concurrently. Specimens can be processed as they come in, 24/7, 365 days a year. BD Diagnostics GeneOhm, 6146 Nancy Ridge Drive San Diego, California 92121 for its Smart Cycler Desktop System. The Smart Cycler Desktop System provides the government with a cost-effective, accurate and rapid means to detect MRSA colonization. In accordance with the FDA "Cleared Packages Inserts", the BD GeneOhm MRSA Assay provides superior performance with a sensitivity of 92.5%. In cases of "unresolved specimens", the BD GeneOhm MRSA allows the user the ability to repeat the PCR using frozen lysate, as opposed to collecting a second swab from the patient. Clinical research indicates that the implementation of universal surveillance, which introduces the testing of all admitted patients, is far more effective than just passive or targeted active surveillance when monitoring for Methicillin-Resistant Staphyloccus aureus (MRSA). The purpose of this acquisition is to reduce and or mitigate the spread of Methicillin-Resistant Staphyloccus aureus (MRSA) throughout VISN 3???s Healthcare Network through active surveillance of cultures. The procurement of the outlined product offerings will add the required value in the management of multi-drug resistant organisms within VISN 3.
- Record
- SN01493911-W 20080130/080128223326 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |